Prolinamides derived from aminophenols as organocatalysts for asymmetric direct aldol reactions
作者:Sornpranart Sathapornvajana、Tirayut Vilaivan
DOI:10.1016/j.tet.2007.07.086
日期:2007.10
site to the prolinamide structure. These compounds were evaluated as organocatalysts for asymmetricaldolreactions between aromatic aldehydes and cyclohexanone. Very good yields, diastereoselectivities, and enantioselectivities were achieved in both organic solvents and water. The importance of the additional hydrogen bonding site was confirmed by comparative experiments with prolinamide derivatives
NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS
申请人:Bessis Anne-Sophie
公开号:US20090124625A1
公开(公告)日:2009-05-14
The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
申请人:Bessis Anne-Sophie
公开号:US20120277237A1
公开(公告)日:2012-11-01
The present invention relates to novel compounds of formula I wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
Alkynyl derivatives as modulators of metabotropic glutamate receptors
申请人:Addex Pharma SA
公开号:EP2426115A2
公开(公告)日:2012-03-07
The present invention relates to novel compounds of formula I wherein W, n, X and W' are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 ("mGluR5") which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
本发明涉及式 I 的新型化合物,其中 W、n、X 和 W' 在描述中定义;本发明化合物是代谢谷氨酸受体-亚型 5("mGluR5")的调节剂,可用于治疗中枢神经系统疾病以及受 mGluR5 受体调节的其他疾病。